ERBB2 and breast carcinoma: In terms of targeting HH signaling, although the current clinical activities are towards broad therapeutic effects in TNBC or HER-2 positive breast cancer—two BCSC-enriched breast cancer types—it is also promising to effectively eliminate BCSCs in metastatic and relapsed breast cancer.